il-2
Showing 1 - 25 of 60
NSCLC, Carcinoma Breast Trial in Suzhou (Vinorelbine, Radiotherapy, PD-1/PD-L1 inhibitor)
Not yet recruiting
- Carcinoma, Non-Small-Cell Lung
- Carcinoma Breast
- Vinorelbine
- +4 more
-
Suzhou, ChinaSecond Affiliated Hospital of Soochow University
Oct 29, 2022
Colorectal Cancer, Hematologic Malignancy, Rectum Cancer Trial in Cleveland (Vactosertib, Fludarabine Phosphate,
Recruiting
- Colorectal Cancer
- +11 more
- Vactosertib
- +4 more
-
Cleveland, OhioUniversity Hospitals Cleveland Medical Center, Case Comprehensiv
Jan 18, 2023
Ovarian Cancer, Fallopian Tube Adenocarcinoma, Primary Peritoneal Cavity Cancer Trial in Minneapolis (IP FT516, Enoblituzumab,
Completed
- Ovarian Cancer
- +2 more
- IP FT516
- +2 more
-
Minneapolis, MinnesotaUniversity of Minnesota, Masonic Cancer Center
Apr 12, 2022
Advanced Refractory Solid Tumors Trial in China (Hypofractionated radiotherapy, PD-1 inhibitor, GM-CSF)
Recruiting
- Advanced Refractory Solid Tumors
- Hypofractionated radiotherapy
- +3 more
-
Beijing, China
- +15 more
Aug 8, 2022
Advanced Breast Cancer, Advanced Lung Cancer Trial (Tumor-infiltrating lymphocytes, IL-2)
Not yet recruiting
- Advanced Breast Cancer
- Advanced Lung Cancer
- Tumor-infiltrating lymphocytes
- IL-2
- (no location specified)
Oct 26, 2023
Non Small Cell Lung Cancer, Colorectal Cancer, Breast Cancer Trial in Huntersville (FT536, Cyclophosphamide, Fludarabine)
Recruiting
- Non Small Cell Lung Cancer
- +6 more
- FT536
- +10 more
-
Scottsdale, Arizona
- +4 more
Dec 27, 2022
Solid Tumor Trial (Tumor Infiltrating Lymphocytes, Fludarabine, Cyclophosphamide Capsules)
Not yet recruiting
- Solid Tumor
- Tumor Infiltrating Lymphocytes
- +3 more
- (no location specified)
Dec 11, 2022
Advanced Solid Tumors Trial in Chongqing (TC-N201 cells, IL-2, Fludarabine)
Recruiting
- Advanced Solid Tumors
- TC-N201 cells
- +4 more
-
Chongqing, ChinaTCRCure Biopharma Ltd.
May 25, 2023
Solid Tumors Trial (TCR-T cells, Fludarabine, Cyclophosphamide Capsules)
Not yet recruiting
- Solid Tumors
- TCR-T cells
- +4 more
- (no location specified)
Dec 12, 2022
Purpura, Schoenlein-Henoch Trial in Changchun (IL-2)
Completed
- Purpura, Schoenlein-Henoch
- IL-2
-
Changchun, Changchun/JiLin, ChinaSirui Yang
Aug 16, 2022
Amyotrophic Lateral Sclerosis Trial in Beijing (IL-2)
Recruiting
- Amyotrophic Lateral Sclerosis
- IL-2
-
Beijing, Beijing, ChinaPeking University Third Hospital
Aug 11, 2021
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma Trial in United States (IOV-2001, Low dose IL-2, High dose IL-2)
Recruiting
- Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma
- IOV-2001
- +3 more
-
Tampa, Florida
- +5 more
Jan 31, 2022
Acute Myeloid Leukemia Refractory, Acute Myeloid Leukemia, Relapsed, Adult Trial in Nijmegen (UCB-NK cells, IL-2)
Recruiting
- Acute Myeloid Leukemia Refractory
- Acute Myeloid Leukemia, Relapsed, Adult
- UCB-NK cells
- IL-2
-
Nijmegen, NetherlandsRadboud University Medical Center
Nov 10, 2021
Metastatic Clear Cell Renal Cell Carcinoma Trial in Dallas (IL-2, Stereotactic Ablative Body Radiation Therapy)
Completed
- Metastatic Clear Cell Renal Cell Carcinoma
- IL-2
- Stereotactic Ablative Body Radiation Therapy
-
Dallas, TexasUniversity of Texas Southwestern Medical Center
Jul 28, 2021
Systemic Lupus Erythematosus Trial in Changchun (IL-2)
Completed
- Systemic Lupus Erythematosus
- IL-2
-
Changchun, Changchun/Jilin, ChinaSirui Yang
Aug 16, 2022
Cervical Carcinoma Trial in Chongqing (TC-E202 cells, IL-2, Fludarabine)
Recruiting
- Cervical Carcinoma
- TC-E202 cells
- +3 more
-
Chongqing, Chongqing, ChinaXiaochun Cheng
Oct 20, 2022
R/R CD19-Positive B-Cell Malignancies, Indolent Non-Hodgkin Lymphoma, Aggressive Non-Hodgkin Lymphoma Trial (CNTY-101, IL-2,
Recruiting
- R/R CD19-Positive B-Cell Malignancies
- +2 more
- CNTY-101
- +2 more
-
Detroit, Michigan
- +1 more
Dec 21, 2022
IL-2 "SELECT" Tissue Collection Protocol in Advanced Melanoma
Completed
- Malignant Melanoma
- IL-2
-
Boston, MassachusettsBeth Israel Deaconess Medical Center
Jan 13, 2021
Leukemia, Acute Myeloid, Leukemia, Acute Lymphoblastic Trial in Minsk (Expanded Haploidentical Natural Killer cells, IL-2)
Completed
- Leukemia, Acute Myeloid
- Leukemia, Acute Lymphoblastic
- Expanded Haploidentical Natural Killer cells
- IL-2
-
Minsk, Minsk Region, BelarusBelarussian Research Center for Pediatric Oncology, Hematology a
Feb 28, 2022
Amputation, Traumatic, Amputation;Traumatic;Old, Face Injury Trial in Boston (IL-2)
Terminated
- Amputation, Traumatic
- +4 more
- IL-2
-
Boston, MassachusettsBrigham and Women's Hospital
Jul 22, 2021
Melanoma, NSCLC, Squamous Cell Carcinoma of Head and Neck Trial in United States (GEN-011, IL-2, Fludarabine)
Terminated
- Melanoma
- +8 more
- GEN-011
- +3 more
-
Gilbert, Arizona
- +7 more
Jul 13, 2022